NCT05188261View on ClinicalTrials.gov

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

March 9, 2022

Study Completion Date

March 21, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

IW-3300

A single dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.

DRUG

Placebo

A single dose of placebo administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.

Trial Locations (1)

78744

PPD, Austin

Sponsors
All Listed Sponsors
lead

Ironwood Pharmaceuticals, Inc.

INDUSTRY

NCT05188261 - A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers | Biotech Hunter | Biotech Hunter